Form 4: Teladoc Health Executive Trades TDOC Shares

Joseph Ronald Catapano, Chief Accounting Officer at Teladoc Health, Inc., reported transactions involving common stock, including the acquisition of performance and restricted stock units and the sale of shares to cover tax obligations.

Summary

• Joseph Ronald Catapano, Chief Accounting Officer of Teladoc Health, Inc., engaged in several transactions on June 1st and June 2nd, 2026.
• He acquired 39 performance stock units and 833 restricted stock units.
• These units convert to common stock on a one-for-one basis.
• He also sold 284 shares of common stock at $7.627 per share to cover tax withholding obligations related to the vesting of his performance and restricted stock units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily details routine executive stock transactions and vesting schedules rather than significant financial performance or strategic shifts.

Positives

• Acquisition of 39 performance stock units, indicating potential future value tied to company performance.
• Acquisition of 833 restricted stock units, representing a long-term incentive and commitment to the company.
• Vesting schedules for both performance and restricted stock units are detailed, providing transparency on future share issuances.

Negatives

• Sale of 284 shares to cover tax withholding obligations, which reduces the executive's direct shareholding.

Risks

• The filing does not explicitly mention any risks.

Future Outlook

The filing details vesting schedules for performance and restricted stock units, indicating future potential share issuances based on company performance and continued employment.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for executive stock transactions. The acquisition of performance and restricted stock units is a common component of executive compensation in the healthcare technology sector, aligning management interests with shareholder value.

Stakeholder Impact

• Shareholders: The transactions reflect standard executive compensation practices and do not immediately indicate a significant change in beneficial ownership that would impact share price, though future vesting could lead to increased float.

Next Steps

• Continued vesting of performance stock units as per the schedule (one-third on March 1, 2026, with remainder in eight quarterly installments).
• Continued vesting of restricted stock units as per the schedule (one-third on March 1, 2026, with remainder in eight quarterly installments).

Key Dates

Keywords

Form 4, SEC Filing, Teladoc Health, TDOC, Stock Transaction, Executive Compensation, Stock Options, Restricted Stock Units, Performance Stock Units, Insider Trading